Evidence map›Paper›PMID 23954450›Full record

Trial reportThe Lancet. Infectious diseases2013

Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.

Betina Durovni, Valeria Saraceni, Lawrence H Moulton, Antonio G Pacheco, Solange C Cavalcante, Bonnie S King, Silvia Cohn, Anne Efron, Richard E Chaisson, Jonathan E Golub

4 registry-linked trialsOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The Lancet. Infectious diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 64 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 5 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00107887 phase4completednot on this map

Impact of TB Preventive Therapy for HIV/TB Co-infected Patients With Access to Highly Active Antiretroviral Therapy in Rio de Janeiro, Brazil: A Phased Implementation Trial

TypeinterventionalSponsorJohns Hopkins UniversityRan2005 to 2010Enrolled17,415ConditionsTuberculosis, HIV InfectionsArmsINH preventive therapy, TST (tuberculin skin test)
NCT03302299 phase4completednot on this mapstarted 2017, after this paper: background citation

URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence

TypeinterventionalSponsorUniversity of California, San FranciscoRan2017 to 2021Enrolled302ConditionsTuberculosis, HIV/AIDS, Alcohol AbuseArmsIsoniazid 300 Mg ORAL TABLET, Pyridoxine 25 Mg Oral Tablet
NCT03537872 nacompletednot on this mapstarted 2018, after this paper: background citation

PROvide MIner-friendly SErvices for Integrated TB/HIV Care in Lesotho Study (PROMISE Study)

TypeinterventionalSponsorColumbia UniversityRan2018 to 2019Enrolled248ConditionsHIVArmsMiner-Friendly (MF) Service Venues TB/HIV Integration Strategies, Public Sector (PS) Health Facilities TB/HIV Integration Strategies
NCT04557176 naactive not recruitingnot on this mapstarted 2020, after this paper: background citation

TB Screening Improves Preventive Therapy Uptake Trial

TypeinterventionalSponsorUniversity of California, San FranciscoRan2020 to 2025Enrolled1,719ConditionsTuberculosis, Latent Tuberculosis, Tuberculosis Prevention, HIVArmsCRP, point-of-care assay
3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 5 syntheses or guidelines pooled it, 107 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Completion of isoniazid preventive therapy among human immunodeficiency virus positive adults in urban Malawi.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2018
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Cost-effectiveness of tuberculosis screening and isoniazid treatment in the TB/HIV in Rio (THRio) Study.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2014
    Trial
  17. Trial
  18. Trial
  19. Observational
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Betina DurovniMunicipal Health Secretariat, Rio de Janeiro, Brazil; Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Valeria Saraceni
Lawrence H Moulton
Antonio G Pacheco
Solange C Cavalcante
Bonnie S King
Silvia Cohn
Anne Efron
Richard E Chaisson
Jonathan E Golub
Johns Hopkins University · USFundação Oswaldo Cruz · BRJohns Hopkins Medicine · USUniversidade Federal do Rio de Janeiro · BR

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Innovative Approaches for Tuberculosis Control in BrazilU2RTW006885 · FIC · JOHNS HOPKINS UNIVERSITY · PI GOLUB, JONATHAN E. · 2005 to 2014
$2.3M
CLINICAL RESEARCH IN TUBERCULOSISK24AI001637 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CHAISSON, RICHARD E. · 1999 to 2009
$1.3M
Epidemiologic Strategies for Tuberculosis ControlK01AI066994 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GOLUB, JONATHAN E. · 2005 to 2009
$564k
FIC NIH HHS U2R TW006885NIAID NIH HHS AI001637NIAID NIH HHS AI066994NIAID NIH HHS K01 AI066994NIAID NIH HHS K24 AI001637NIAID NIH HHS P30 AI094189PHS HHS U2RTW006885
6 · The paper itself

Abstract

backgroundPreventive therapy for tuberculosis in patients with HIV is effective, but it has not been widely implemented in moderate or high-burden settings. We assessed the effect of widespread use of isoniazid preventive therapy on rates of tuberculosis and death in people with HIV in Brazil.

methodsWe did a stepped wedge, cluster-randomised trial with patients actively enrolled in 29 HIV clinics in Rio de Janeiro. Clinic staff were trained in tuberculosis screening, use of tuberculin skin tests, and use of isoniazid preventive therapy. Clinics were randomly allocated a date to begin the intervention period, with two clinics beginning the intervention every 2 months starting from Sept 1, 2005. The primary outcome was tuberculosis incidence alone or combined with death in the control versus intervention periods until Aug 31, 2009. This trial is registered at ClinicalTrials.gov, number NCT00107887.

resultsOf 17,413 patients in the cohort, 12,816 were eligible for the intervention. Overall, there were 475 tuberculosis cases and 838 deaths. The intervention increased the rate of patients receiving skin tests from 19 per 100 person-years to 59 per 100 person-years, and from 36 per 100 person-years to 144 per 100 person-years for those eligible for isoniazid preventive therapy. In the control period, 221 cases of tuberculosis were diagnosed (1.31 per 100 person-years) compared with 254 (1.10 per 100 person-years) in the intervention period (unadjusted hazard ratio [HR] 0.87; 95% CI 0.69-1.10). Rates of tuberculosis incidence or death were 3.64 and 3.04 per 100 person-years, respectively (0.76; 95% CI 0.66-0.87). When adjusted for age, sex, entry CD4 count, and use of antiretroviral therapy, the HR for tuberculosis was 0.73 (95% CI 0.54-0.99) and for tuberculosis or death was 0.69 (0.57-0.83).

interpretationOperational training aimed at increasing tuberculosis screening, provision of tuberculin skin tests, and use of isoniazid preventive therapy in Brazilian HIV clinics significantly reduced incident tuberculosis and death. Thus, scale-up of preventive therapy for HIV-infected patients in settings of moderate tuberculosis incidence is achievable and should be widely implemented in Brazil and elsewhere.

fundingBill & Melinda Gates Foundation and the National Institutes of Health.

Indexed as

AdolescentAdultAgedAged, 80 and overAnti-Retroviral AgentsAntitubercular AgentsBrazilFemaleHIV InfectionsHumansIncidenceIsoniazidMaleMiddle AgedTuberculosisYoung AdultAnti-Retroviral AgentsAntitubercular AgentsIsoniazid

Identifiers

PMID23954450
PMCPMC3899698
OpenAlexW2161314997

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.